One Global Service Provider Limited received in-principal approval from BSE Limited for the preferential issue of 7,06,068 equity shares at a price of not less than ₹558.93 each. The issuance is structured as a share swap to non-promoter categories.

The approval was granted under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This clearance does not constitute final listing approval; the company must separately comply with all listing requirements post-allotment.

Regulatory conditions and compliance

BSE advised the company to strengthen internal controls to monitor trades executed by proposed allottees. This measure aims to prevent non-compliance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Key directives include:

• Obtaining an undertaking from allottees confirming they will not engage in intra-day trading or sell shares until the allotment date.
• Ensuring the issuer verifies compliance with Regulation 167(6) of SEBI ICDR Regulations, 2018.
• Noting that any observed non-compliance after verification may impact the listing of such shares.

Listing timeline and obligations

Upon allotment, the company is required to file a listing application without delay, adhering to Regulation 14 of the LODR Regulations. As per Schedule XIX – Para (2) of ICDR Regulations and SEBI circular dated June 21, 2023, the application must be made within twenty days from the date of allotment. Failure to comply will attract fines as specified in the circular.

The exchange reserves the right to withdraw the in-principal approval if submitted information is found incomplete, incorrect, misleading, or false. Non-compliance with Exchange Rules, Bye-laws, Regulations, LODR Regulations, ICDR Regulations, or guidelines issued by statutory authorities also triggers this withdrawal clause.

One Global Service Provider Limited shareholders approved the audited financial statements for FY26, marking a year of significant growth in revenue and profitability. The 34th Annual General Meeting, held on September 29, 2026, also sanctioned key strategic moves including a preferential issue to acquire stakes in two diagnostic entities.

The meeting, conducted via Video Conferencing, saw members adopt the standalone audited financials alongside reports from the Board of Directors and Statutory Auditors. A dividend on equity shares for FY26 was also declared. Additionally, shareholders ratified the re-appointment of Sanjay Upadhyay as Managing Director and approved the appointment of SDPM & Co., Chartered Accountants, as Statutory Auditors for a second five-year term.

Strategic Acquisitions and Capital Structure

A central focus of the AGM was the approval of special resolutions facilitating corporate expansion. Members authorized an increase in authorized share capital and the issuance of 7,06,068 equity shares on a preferential basis. This non-cash consideration is earmarked for acquiring a 51% equity stake each in Matrix Labs Diagnocare Private Limited and Matrix Labs Private Limited.

These acquisitions are part of the company’s strategy to strengthen its presence in the healthcare, diagnostics, and In-Vitro Diagnostics (IVD) sector. The company also highlighted the successful amalgamation of Plus Care Internationals Private Limited, which has broadened its capabilities in the healthcare ecosystem.

Financial Performance Highlights

The Chairman reported robust financial metrics for FY26 compared to the previous year. Total revenue nearly tripled, while Profit After Tax (PAT) more than tripled, reflecting strong operational leverage.

Note: Percentages calculated based on source figures.

What the Numbers Show

The divergence between revenue growth (+237.4%) and PAT growth (+276.4%) indicates significant margin expansion during FY26. While net worth nearly doubled, the Return on Equity jumped from 25.75% to 49.21%, suggesting that the company is generating substantially higher returns on its capital base, likely driven by the operational synergies from the recent amalgamation and improved asset utilization.

Other Key Resolutions

Beyond financial adoption and acquisitions, the AGM addressed several governance and operational matters:

• Approval for overall borrowing limits under Section 180(1)(c) of the Companies Act, 2013.
• Authorization to create mortgages or charges on assets under Section 180(1)(a).
• Approval for loans, inter-corporate deposits, and guarantees exceeding prescribed limits under Section 186.
• Ratification of remuneration payable to Cost Auditors J.H. Survase & Co.
• Approval for material related-party transactions with Lifenity Health Limited.

The voting results for these resolutions were conducted via remote e-voting and e-voting during the meeting, with detailed outcomes to be submitted separately as per SEBI Listing Regulations.